Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
On the Downside Radar. Closed at $3.30, 43% below $5.76, its close on the day of its Oct 28 private placement. Of biotech stocks this far below their close on the day of a recent offering, 76% were lower 60 trading days later (median -29%). How we know
$1.4MCash on Hand
2.5mo Cash Runway
Follow GRDX by emailGet an email when GRDX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about GRDX, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 30, 2026 ·
Leadership GridAI amended the CFO consulting agreement with BPC Consulting, effective September 1, 2026. The interim CFO, Anna Skowron, gets a $27,000 monthly retainer and up to 250,000 RSUs, with vesting tied to service dates and milestones. Form 8-K · SEC filing
Oct 28, 2026 ·
Financing GridAI agreed on October 22, 2026 to sell pre-funded warrants and common warrants for gross proceeds of about $2,150,000 at a combined price of $4.65 per pre-funded warrant and accompanying common warrant. Common warrants have an exercise price of $4.525 and five-year terms, sold in private placements. Form 8-K · SEC filing
Oct 28, 2026 ·
Financing GridAI increased its secured convertible note to Pronghorn Resources to $5,000,000 after a $1,500,000 advance on October 22, 2026. The note matures on the earlier of December 31, 2026 or a change of control, and bears 7% interest after maturity. Form 8-K · SEC filing
Oct 23, 2026 ·
Leadership Manpreet Uppal resigned from the Board of Directors and all Board committees, effective October 19, 2026. The resignation was not due to any disagreement with the Company on its operations, policies or practices. Form 8-K · SEC filing
Oct 19, 2026 ·
Financing Registers resale of up to 9,908,766 shares by selling stockholders from private placements, with GridAI receiving no offering proceeds. Company reports cash of $1.4 million, $224.9 million accumulated deficit, and a going-concern doubt; it estimates liquidity for at least eighteen months. Form 424B3 · SEC filing
Oct 7, 2026 ·
Financing GridAI amended and restated its secured convertible note with Pronghorn Resources, LLC, reflecting a third loan of $536,000 for an aggregate principal amount of $3,500,000. The security agreement was amended to refer to the new note. Form 8-K · SEC filing
Sep 18, 2026 ·
Amended quarterly report for the period ended Jun 30, 2026 Form 10-Q/A · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
GRDX holds $1.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $1.6M/quarter from operations,
an estimated runway of 2.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:65 · High
Cash runway 2 months +40
Going-concern doubt in the latest 10-Q +15These circumstances raise substantial doubt about its ability to continue as a going concern.10-Q, Nov 2026
Share count +205% in a year +20
Raised after last reported balance sheet (Oct 2026) -10
Share count 10,265,090 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full GRDX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GRDX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.